Tumor types with reported objective response rates (ORR) of >11 to anti-PD-1 or PD-L1 therapies27 included top c-Score expressors (mesothelioma [MESO], lung squamous cell carcinoma [LUSC], kidney renal clear cell carcinoma [KIRC], HNSC, CESC), though other modest and strong responders to ICIs were seen throughout the c-Score expression spectrum (Fig. 1c). This evidence concerns the gene PDCD1 and neoplasm.